Andrew Sinclair - 06 Jun 2024 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Reporting relationship: Director
Issuer ticker: SLNO
Reported as of: 06 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2024, 20:51:50 UTC
Prior SEC filing: 07 Jun 2024
Next SEC filing: 23 Aug 2024
Source filing: View source filing
Reporting owner signature: /s/ Anish Bhatnagar, Attorney-in-Fact

Key filing fact

Andrew Sinclair filed Form 4 for SOLENO THERAPEUTICS INC (SLNO) on 10 Jun 2024.

Key facts

This page summarizes Andrew Sinclair's Form 4 filing for SOLENO THERAPEUTICS INC (SLNO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 10 Jun 2024, 20:51.

Change

Previous filing in this sequence was filed on 07 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SLNO transaction

Common Stock

Award

Transaction value: $0
Shares: +6,500
Change %
Price: $0.000000
Shares after: 6,500
Date: 06 Jun 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 6, 2024 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date.